Annex II — Financial tender Financial Evaluation  Title:  Reference:  Lot 5:  Vaccine effectiveness against COVID-19 and seasonal influenza among patients presenting to primary care physicians in EU/EEA Vaccine Effectiveness, Burden and Impact Studies of COVID-19 and Influenza OJ/2021/DPR/12924 The table below is automatically filled in from the first sheet. It is not editable. The scenario in the table is only meant for evaluation purposes and does not constitute a commitment on the part of ECDC to request this volume of services. The reference price below must not exceed the estimated maximum budget for this contract: € 4'700'000 Tenderer (name): Please print/upload BOTH SHEETS (Financial tender and Financial evaluation). Unit price at  coordination level Unit price at study  site level Expected  repetition(s) of  deliverable  Expected Number of  study sites  Total price (unit price x  scenario) € 0 4 € 0 € 0 40 € 0 € 0 2 € 0 € 0 4 € 0 € 0 16 € 0 € 0 4 € 0 € 0 8 € 0 € 0 1 € 0 € 0 4 € 0 € 0 4 € 0 € 0 40 € 0 € 0 10 € 0 € 0 4 € 0 € 0 4 € 0 € 0 1 30 € 0 € 0 8 € 0 € 0 8 € 0 € 0 1 € 0  Deliverables DL 5.1.1 Annual work plan for thelot, kick-off teleconferencewith ECDC and  minutes provided. DL 5.1.2 Minutes of themonthly teleconferences between ECDC and the  contractor DL 5.1.3 Organisation of a faceto facemeeting, including meeting report DL 5.1.4 Onlineannual meeting (approximately 160 participants) DL 5.1.5 Onlinetechnical meeting (approximately 60 participants) DL 5.4.5 Report on pilot, assesment on data transfers to TESSy from study site,  national and EU/EEA levels. DL 5.1.7 Reports on progress during each specific contract DL 5.1.8 Draft report with Standard Operating Procedures on coordination of  studies to transfer knowledge gained through the project DL 5.2.1 Updated list of participating countries/sites joining thenetwork DL 5.2.2 Report describing all participating sites DL 5.3.1 Site/ specific training visit (In principleonly virtual trainings, visits are  foreseen. If travel requested by ECDC costs will be reimbursed see contract  article I.5.3)  DL 5.3.2 Training workshops for study sites / information sharing workshop  DL 5.3.3 Report on capacity building  DL 5.4.1 EU/EEA protocol for integrated vaccineeffectiveness (VE) studies against  seasonal influenza and COVID-19 among outpatients. Price per protocol. DL 5.4.2 Draft or updatecountry- and site-specific Standard Operating  Procedures to implement EU/EEAprotocols. Cost includes initial investment in  thesetting up thestudy at site. Pricefor up to 30 study sites. DL 5.4.3 Develop technical documents related to COVID-19 vaccine  effectiveness among outpatients (such as TESSy reporting protocol, TESSy  metadata, definitions)  DL 5.4.4 Develop technical documents related to seasonal influenza vaccine  effectiveness among outpatients (such as TESSy reporting protocol, TESSy  metadata, definitions) (priceper technical document). DL 5.1.6 Organisation of an international scientific advisory group  teleconference Page 14 of 15